187 related articles for article (PubMed ID: 37703579)
1. Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRASG12C-Mutant Pancreatic and Lung Cancers.
Khan HY; Nagasaka M; Aboukameel A; Alkhalili O; Uddin MH; Bannoura SF; Mzannar Y; Azar I; Beal EW; Tobon ME; Kim SH; Beydoun R; Baloglu E; Senapedis W; El-Rayes BF; Philip PA; Mohammad RM; Shields AF; Al Hallak MN; Azmi AS
Mol Cancer Ther; 2023 Dec; 22(12):1422-1433. PubMed ID: 37703579
[TBL] [Abstract][Full Text] [Related]
2. Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancers.
Khan HY; Nagasaka M; Aboukameel A; Alkhalili O; Uddin MH; Bannoura S; Mzannar Y; Azar I; Beal E; Tobon M; Kim S; Beydoun R; Baloglu E; Senapedis W; El-Rayes B; Philip PA; Mohammad RM; Shields AF; Al-Hallak MN; Azmi AS
bioRxiv; 2023 Mar; ():. PubMed ID: 37034616
[TBL] [Abstract][Full Text] [Related]
3. CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non-Small Cell Lung Cancer.
Prahallad A; Weiss A; Voshol H; Kerr G; Sprouffske K; Yuan T; Ruddy D; Meistertzheim M; Kazic-Legueux M; Kottarathil T; Piquet M; Cao Y; Martinuzzi-Duboc L; Buhles A; Adler F; Mannino S; Tordella L; Sansregret L; Maira SM; Graus Porta D; Fedele C; Brachmann SM
Cancer Res; 2023 Dec; 83(24):4130-4141. PubMed ID: 37934115
[TBL] [Abstract][Full Text] [Related]
4. Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer.
Sabari JK; Velcheti V; Shimizu K; Strickland MR; Heist RS; Singh M; Nayyar N; Giobbie-Hurder A; Digumarthy SR; Gainor JF; Rajan AP; Nieblas-Bedolla E; Burns AC; Hallin J; Olson P; Christensen JG; Kurz SC; Brastianos PK; Wakimoto H
Clin Cancer Res; 2022 Aug; 28(15):3318-3328. PubMed ID: 35404402
[TBL] [Abstract][Full Text] [Related]
5. Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C-Mutant Cancers.
Khan HY; Nagasaka M; Li Y; Aboukameel A; Uddin MH; Sexton R; Bannoura S; Mzannar Y; Al-Hallak MN; Kim S; Beydoun R; Landesman Y; Mamdani H; Uprety D; Philip PA; Mohammad RM; Shields AF; Azmi AS
Cancer Res Commun; 2022 May; 2(5):342-352. PubMed ID: 35573474
[TBL] [Abstract][Full Text] [Related]
6. SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling.
Fedele C; Li S; Teng KW; Foster CJR; Peng D; Ran H; Mita P; Geer MJ; Hattori T; Koide A; Wang Y; Tang KH; Leinwand J; Wang W; Diskin B; Deng J; Chen T; Dolgalev I; Ozerdem U; Miller G; Koide S; Wong KK; Neel BG
J Exp Med; 2021 Jan; 218(1):. PubMed ID: 33045063
[TBL] [Abstract][Full Text] [Related]
7. A saturation mutagenesis screen uncovers resistant and sensitizing secondary
Feng S; Callow MG; Fortin JP; Khan Z; Bray D; Costa M; Shi Z; Wang W; Evangelista M
Proc Natl Acad Sci U S A; 2022 May; 119(18):e2120512119. PubMed ID: 35471904
[TBL] [Abstract][Full Text] [Related]
8. BCL-X
Khan S; Wiegand J; Zhang P; Hu W; Thummuri D; Budamagunta V; Hua N; Jin L; Allegra CJ; Kopetz SE; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
J Hematol Oncol; 2022 Mar; 15(1):23. PubMed ID: 35260176
[TBL] [Abstract][Full Text] [Related]
9. Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma.
Aboukameel A; Muqbil I; Senapedis W; Baloglu E; Landesman Y; Shacham S; Kauffman M; Philip PA; Mohammad RM; Azmi AS
Mol Cancer Ther; 2017 Jan; 16(1):76-87. PubMed ID: 28062705
[TBL] [Abstract][Full Text] [Related]
10. A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer.
Wei D; Wang L; Zuo X; Maitra A; Bresalier RS
Clin Cancer Res; 2024 Feb; 30(4):655-662. PubMed ID: 37831007
[TBL] [Abstract][Full Text] [Related]
11. Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers.
Rubinson DA; Tanaka N; Fece de la Cruz F; Kapner KS; Rosenthal MH; Norden BL; Barnes H; Ehnstrom S; Morales-Giron AA; Brais LK; Lemke CT; Aguirre AJ; Corcoran RB
Cancer Discov; 2024 May; 14(5):727-736. PubMed ID: 38236605
[TBL] [Abstract][Full Text] [Related]
12. Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas.
Salmón M; Álvarez-Díaz R; Fustero-Torre C; Brehey O; Lechuga CG; Sanclemente M; Fernández-García F; López-García A; Martín-Guijarro MC; Rodríguez-Perales S; Bousquet-Mur E; Morales-Cacho L; Mulero F; Al-Shahrour F; Martínez L; Domínguez O; Caleiras E; Ortega S; Guerra C; Musteanu M; Drosten M; Barbacid M
J Clin Invest; 2023 Apr; 133(7):. PubMed ID: 36928090
[TBL] [Abstract][Full Text] [Related]
13. Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.
Bungaro M; Novello S; Passiglia F
Curr Treat Options Oncol; 2022 Dec; 23(12):1699-1720. PubMed ID: 36394791
[TBL] [Abstract][Full Text] [Related]
14. KRAS Inhibitor Resistance in
Suzuki S; Yonesaka K; Teramura T; Takehara T; Kato R; Sakai H; Haratani K; Tanizaki J; Kawakami H; Hayashi H; Sakai K; Nishio K; Nakagawa K
Clin Cancer Res; 2021 Oct; 27(20):5697-5707. PubMed ID: 34365406
[TBL] [Abstract][Full Text] [Related]
15. Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C.
Weiss A; Lorthiois E; Barys L; Beyer KS; Bomio-Confaglia C; Burks H; Chen X; Cui X; de Kanter R; Dharmarajan L; Fedele C; Gerspacher M; Guthy DA; Head V; Jaeger A; Núñez EJ; Kearns JD; Leblanc C; Maira SM; Murphy J; Oakman H; Ostermann N; Ottl J; Rigollier P; Roman D; Schnell C; Sedrani R; Shimizu T; Stringer R; Vaupel A; Voshol H; Wessels P; Widmer T; Wilcken R; Xu K; Zecri F; Farago AF; Cotesta S; Brachmann SM
Cancer Discov; 2022 Jun; 12(6):1500-1517. PubMed ID: 35404998
[TBL] [Abstract][Full Text] [Related]
16. KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges.
Moldvay J; Tímár J
Pathol Oncol Res; 2023; 29():1611580. PubMed ID: 38239281
[TBL] [Abstract][Full Text] [Related]
17. FBXL16 promotes cell growth and drug resistance in lung adenocarcinomas with KRAS mutation by stabilizing IRS1 and upregulating IRS1/AKT signaling.
Morel M; Long W
Mol Oncol; 2024 Mar; 18(3):762-777. PubMed ID: 37983945
[TBL] [Abstract][Full Text] [Related]
18. Sotorasib Tackles KRASG12C-Mutated Pancreatic Cancer.
Cancer Discov; 2022 Apr; 12(4):878-879. PubMed ID: 35373275
[TBL] [Abstract][Full Text] [Related]
19. Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer.
Macaya I; Roman M; Welch C; Entrialgo-Cadierno R; Salmon M; Santos A; Feliu I; Kovalski J; Lopez I; Rodriguez-Remirez M; Palomino-Echeverria S; Lonfgren SM; Ferrero M; Calabuig S; Ludwig IA; Lara-Astiaso D; Jantus-Lewintre E; Guruceaga E; Narayanan S; Ponz-Sarvise M; Pineda-Lucena A; Lecanda F; Ruggero D; Khatri P; Santamaria E; Fernandez-Irigoyen J; Ferrer I; Paz-Ares L; Drosten M; Barbacid M; Gil-Bazo I; Vicent S
Nat Commun; 2023 Oct; 14(1):6332. PubMed ID: 37816716
[TBL] [Abstract][Full Text] [Related]
20. An evaluation of sotorasib for the treatment of patients with non-small cell lung cancer with KRASG12C mutations.
Strohbehn GW; Sankar K; Qin A; Kalemkerian GP
Expert Opin Pharmacother; 2022 Oct; 23(14):1569-1575. PubMed ID: 36217844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
